Skip to main content

Autologous Fat Injection — Historical Bulking Agent

Autologous fat injection was one of the earliest biological bulking agents in urology (early 1990s) — attractive as a readily available, non-immunogenic, autologous material with no cost for the injectable substance itself. It has been effectively abandoned because the only RCT showed no efficacy over saline placebo and a patient died from pulmonary fat embolism.[1][2]

Composition & Material Properties​

  • Source: autologous subcutaneous adipose tissue from the anterior abdominal wall or buttock, harvested via standard liposuction.[3]
  • Composition: mature adipocytes + stromal connective tissue, blood vessels, and adipose-derived stem/progenitor cells.
  • Harvest: ~30 cc per session.[1]
  • Injection volume: 10–30 cc per session (mean ~14.8 cc).[5]
  • Autologous → non-immunogenic — no skin testing, no allergic reaction, no granuloma.
  • Biodegradable: significant resorption (17–49%) is the fundamental limitation.[8]
  • No material cost.[5]

Mechanism​

Two proposed mechanisms:[5][4][6]

  1. Immediate bulking — Su 1998 documented increased minimal urethral resistance (0.122 → 0.205, p = 0.023) in successful cases (no change in failures).
  2. Fat-graft remodeling — three-zone model (Kato): superficial surviving zone, regenerating zone with CD34+/Ki67+ stem/progenitor cells + MAC2+ macrophages, and central necrotizing zone where adipogenesis fails and M2-macrophage cicatrization predominates. Long-term, adipose tissue is progressively replaced by fibrosis, inflammation, and vacuolar tissue.[7]

Dmochowski & Appell summary: initially effective in > 50% of women, but resorption and fibrous replacement hamper graft stability.[4]

Injection Technique​

Two-stage:[1][3][5]

  • Harvest: tumescent local at abdomen / buttock, ~30 cc; variable processing (centrifugation, sedimentation, or washing).
  • Periurethral injection: local + IV sedation; cystoscopic guidance; submucosal bladder neck / proximal urethra; mean 14.8 ± 4.8 cc per session; 1–4 sessions at 1–3-month intervals.
  • Misplacement rate notably high: 19% of fat injections in wrong site (intra-urethral, intravaginal, intravesical) vs 6% for saline in the Lee RCT.[2]

Clinical Efficacy​

The Pivotal RCT — Lee 2001​

The only double-blind RCT for SUI bulking with autologous fat:[1]

  • 68 women: periurethral fat (n = 35) vs saline placebo (n = 33).
  • 3-month cure/improvement: 22.2% fat vs 20.7% saline — no significant difference (RR 0.98; 95% CI 0.75–1.29).
  • No change in MUCP or LPP in either group.
  • Complications: 32% per fat injection vs 11% for saline (RR 2.84; 95% CI 1.51–5.35).
  • One patient died of pulmonary fat embolism 3 days after a second injection.

JAMA scientific review (Holroyd-Leduc 2004): no difference in subjective cure/improvement (RR 0.98), NNH 5 for complications, treatment-related death.[10]

Uncontrolled Pre-RCT Studies​

StudynFollow-upOutcome
Santarosa / Blaivas 199415 W, 6 M18 mo meanWomen with ISD: 83% improved at 1 mo; 78% lasting after 1–4 injections. Men: only 1/6 improved. Hypermobility: 0% improved.[3]
Su 199826 (recurrent SUI)≥ 12 mo50% dry, 15.4% improved; mean 14.8 cc.[5]
Dmochowski / Appell 2000— (review)—Initially > 50% effective but resorption / fibrous replacement undermine durability.[4]

The discrepancy between uncontrolled series and the placebo-controlled Lee RCT is striking — the equivalent saline-arm response suggests substantial placebo effect in bulking-agent trials.[2]

Male Post-Prostatectomy SUI​

Uniformly poor: Santarosa / Blaivas — 1 of 6 men improved.[3]

Vesicoureteral Reflux​

Palma 1994 — 12 transplant candidates (17 ureters, grade III+): subureteric lipoinjection achieved only 1/17 ureters (5.9%) complete cessation; 83.3% no change. Authors: lipoinjection alone is not a good VUR option.[9]

Safety — The Defining Problem​

Pulmonary Fat Embolism​

The single critical safety issue:[1][13][2]

  • Lee RCT: fatal pulmonary fat embolism 3 days after a second injection — the only treatment-related death in any bulking-agent RCT.[1]
  • Sweat / Lightner 1999: separate non-fatal pulmonary embolism after periurethral autologous fat — required ventilatory support.[13]
  • Mechanism: direct intravascular injection of liquid fat into the periurethral venous plexus → pulmonary embolism. Distinct from particulate migration (which occurs via macrophage phagocytosis).

The 2017 Cochrane review: "The treatment-related death of a patient in a single trial is sufficient evidence to recommend that autologous fat should not be used as a bulking agent."[2]

Other Complications​

  • Urinary retention 6 vs 0 (fat vs saline) in the RCT.
  • UTI 6/91 fat vs 3/98 saline.
  • Urge incontinence 9/68 overall.
  • Misplacement 19% (vs 6% saline).
  • Donor-site liposuction-infection.
  • Overall complication rate 32% per injection vs 11% for saline (RR 2.84).[2]

Fat-Graft Survival​

  • Resorption 17–49% depending on technique, processing, and site.[8]
  • Adipose progressively replaced by fibrosis / inflammation / vacuolar tissue.[7]
  • The periurethral space is a particularly unfavorable recipient site — relatively avascular, mechanically loaded by urethral function.

Autologous Fat in Otolaryngology — A Contrasting Success​

Crude autologous fat failed in the urethra but remains in active use for vocal-fold medialization:[14][15][16][17][18]

  • Campagnolo 2026 SR (13 studies, 472 patients): safe and effective ≥ 12 mo with significant maximum-phonation-time and VHI improvement.
  • Lahav 2021 (n = 22, 36 mo): VHI 73.45 → 44.88; CT confirmed long-term adipose viability.
  • Balouch 2026 (n = 172): equivalent to type I thyroplasty at 6 and 12 mo.
  • Dominguez 2019: short-term equivalence but thyroplasty more durable long-term.

The vocal fold benefits from fat's viscoelastic filler properties (irrelevant in the urethra) and a more favorable recipient environment.

Autologous Fat vs Other Bulking Agents​

ParameterAutologous FatContigenBulkamidMacroplastique
MaterialAutologous biologicXenogeneic biologicSynthetic hydrogelSynthetic particulate
BiodegradableYes (high resorption)YesNoNo
ImmunogenicNoYes (skin test)NoNo
Material costNoneCommercialCommercialCommercial
RCT cure (12 mo)22.2% (= placebo)25–57%47–64%37–75%
Fatal complicationYes (fat embolism)NoNoNo
Complication rate32% per injection~20%LowModerate
Long-term durabilityVery poor5–26% at 3–5 yr86% at 5 yr49% at ≥ 3 yr
Current statusAbandonedDiscontinued (2011)Available (FDA 2020)Available (FDA 2006)

Guideline Position​

  • Cochrane 2017: autologous fat should not be used as a bulking agent (single treatment-related death is sufficient evidence).[2]
  • JAMA Scientific Review (Holroyd-Leduc 2004): no advantage over saline; higher complications; fatal pulmonary embolism.[10]
  • Nature Reviews Urology 2020: discontinued owing to safety concerns.[19]
  • ACOG: does not recommend autologous fat.[2]

Emerging Adipose-Based Regenerative Approaches​

Crude fat has been abandoned, but adipose tissue remains a source for regenerative-medicine approaches that are conceptually distinct from passive bulking.

Adipose-Derived Regenerative Cells (ADRCs)​

Processed cell preparations isolated by enzymatic digestion of lipoaspirate (e.g., Celution): MSCs, endothelial progenitor cells, stromal cells.

  • ADRESU (Gotoh 2020): multicenter, n = 45 men post-prostatectomy — 37.2% ≥ 50% leakage improvement at 52 weeks; no SAEs.[11]
  • Long-term follow-up (Gotoh 2019): 13 patients, mean 69 mo — 10/13 sustained; mean leakage 281.5 g → 119.0 g (57.7% reduction).[12]
  • Choi 2016: phase I in post-prostatectomy SUI.[20]

Concept: functional regeneration of the urethral sphincter, not passive bulking.

Stromal Vascular Fraction (SVF) + Platelet-Rich Fibrin (PRF)​

Maene 2022 pilot (n = 10 women): suburethral SVF + L-PRF — 80% negative cough test at 3 mo, declining to 40% at 9 mo; no AEs.[21] Investigational.

Reconstructive-Urology Relevance​

Patients with prior periurethral fat injection — typically pre-2005 — may present years later with recurrent SUI from graft resorption / fibrous replacement, generally managed today with a midurethral sling or modern bulking agent (Bulkamid).

Limitations Summary​

  • No efficacy over placebo in the only RCT.[1]
  • Fatal pulmonary fat embolism — the only RCT death across all bulking agents.[1][13]
  • 32% per-injection complication rate, NNH 5.[2]
  • 19% misplacement.[2]
  • 17–49% resorption with fibrous replacement.[6][7][8]
  • No urodynamic improvement in opening pressure.[2]
  • Requires liposuction with its own morbidity.
  • Universally recommended against (Cochrane, JAMA, ACOG).
  • Abandoned worldwide as a urethral bulking agent.[19]

See also: Bulkamid, Macroplastique, Contigen, Teflon, Historical Bulking Agents.

References​

1. Lee PE, Kung RC, Drutz HP. Periurethral Autologous Fat Injection as Treatment for Female Stress Urinary Incontinence: A Randomized Double-Blind Controlled Trial. The Journal of Urology. 2001;165(1):153-158. doi:10.1097/00005392-200101000-00037

2. Kirchin V, Page T, Keegan PE, et al. Urethral Injection Therapy for Urinary Incontinence in Women. Cochrane Database of Systematic Reviews. 2017;7:CD003881. doi:10.1002/14651858.CD003881.pub4

3. Santarosa RP, Blaivas JG. Periurethral Injection of Autologous Fat for the Treatment of Sphincteric Incontinence. The Journal of Urology. 1994;151(3):607-611. doi:10.1016/s0022-5347(17)35029-2

4. Dmochowski RR, Appell RA. Injectable Agents in the Treatment of Stress Urinary Incontinence in Women: Where Are We Now? Urology. 2000;56(6 Suppl 1):32-40. doi:10.1016/s0090-4295(00)01019-0

5. Su TH, Wang KG, Hsu CY, et al. Periurethral Fat Injection in the Treatment of Recurrent Genuine Stress Incontinence. The Journal of Urology. 1998;159(2):411-414. doi:10.1016/s0022-5347(01)63935-1

6. Kato H, Mineda K, Eto H, et al. Degeneration, Regeneration, and Cicatrization After Fat Grafting: Dynamic Total Tissue Remodeling During the First 3 Months. Plastic and Reconstructive Surgery. 2014;133(3):303e-313e. doi:10.1097/PRS.0000000000000066

7. Chen X, Wu Y, Liu G. Influence of Recipient Site on the Function and Survival of Fat Grafts. Annals of Plastic Surgery. 2019;82(1):110-115. doi:10.1097/SAP.0000000000001683

8. Liu B, Tan XY, Liu YP, et al. The Adjuvant Use of Stromal Vascular Fraction and Platelet-Rich Fibrin for Autologous Adipose Tissue Transplantation. Tissue Engineering Part C, Methods. 2013;19(1):1-14. doi:10.1089/ten.TEC.2012.0126

9. Palma PC, Ferreira U, Ikari O, Rodrigues Netto N. Subureteric Lipoinjection for Vesicoureteral Reflux in Renal Transplant Candidates. Urology. 1994;43(2):174-177. doi:10.1016/0090-4295(94)90039-6

10. Holroyd-Leduc JM, Straus SE. Management of Urinary Incontinence in Women: Scientific Review. JAMA. 2004;291(8):986-995. doi:10.1001/jama.291.8.986

11. Gotoh M, Shimizu S, Yamamoto T, et al. Regenerative Treatment for Male Stress Urinary Incontinence by Periurethral Injection of Adipose-Derived Regenerative Cells: Outcome of the ADRESU Study. International Journal of Urology. 2020;27(10):859-865. doi:10.1111/iju.14311

12. Gotoh M, Yamamoto T, Shimizu S, et al. Treatment of Male Stress Urinary Incontinence Using Autologous Adipose-Derived Regenerative Cells: Long-Term Efficacy and Safety. International Journal of Urology. 2019;26(3):400-405. doi:10.1111/iju.13886

13. Sweat SD, Lightner DJ. Complications of Sterile Abscess Formation and Pulmonary Embolism Following Periurethral Bulking Agents. The Journal of Urology. 1999;161(1):93-96.

14. Campagnolo AM, Priston J, Nickel V, Benninger M. Vocal Fold Fat Injection for Glottic Insufficiency: Systematic Review. Journal of Voice. 2026;40(2):466-475. doi:10.1016/j.jvoice.2023.09.029

15. Lahav Y, Malka-Yosef L, Shapira-Galitz Y, et al. Vocal Fold Fat Augmentation for Atrophy, Scarring, and Unilateral Paralysis: Long-Term Functional Outcomes. Otolaryngology Head and Neck Surgery. 2021;164(3):631-638. doi:10.1177/0194599820947000

16. Balouch B, Maxwell PJ, Vontela S, Sataloff RT. Long-Term Outcome of Autologous Lipoinjection Medialization Laryngoplasty Versus Type I Thyroplasty. Journal of Voice. 2026;40(2):504-510. doi:10.1016/j.jvoice.2023.10.012

17. Dominguez LM, Villarreal R, Simpson CB. Voice Outcomes of Lipoinjection Versus Medialization Laryngoplasty for Nonparalytic Glottic Insufficiency. The Laryngoscope. 2019;129(5):1164-1168. doi:10.1002/lary.27573

18. Chang WD, Chen SH, Tsai MH, Tsou YA. Autologous Fat Injection Laryngoplasty for Unilateral Vocal Fold Paralysis. Journal of Clinical Medicine. 2021;10(21):5034. doi:10.3390/jcm10215034

19. Hillary CJ, Roman S, MacNeil S, et al. Regenerative Medicine and Injection Therapies in Stress Urinary Incontinence. Nature Reviews Urology. 2020;17(3):151-161. doi:10.1038/s41585-019-0273-4

20. Choi JY, Kim TH, Yang JD, Suh JS, Kwon TG. Adipose-Derived Regenerative Cell Injection Therapy for Postprostatectomy Incontinence: A Phase I Clinical Study. Yonsei Medical Journal. 2016;57(5):1152-1158. doi:10.3349/ymj.2016.57.5.1152

21. Maene A, Deniz G, Bouland C, et al. Suburethral Implantation of Autologous Regenerative Cells for Female Stress Urinary Incontinence Management: Results of a Pilot Study. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2022;278:38-44. doi:10.1016/j.ejogrb.2022.08.028